X

Trial Profile

A first-in-human clinical trial of LTX-002

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 05 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LTX 002 (Primary)
Indications Amyotrophic lateral sclerosis
Focus Adverse reactions; First in man

Most Recent Events

05 Nov 2024 New trial record
30 Oct 2024 According to a Leal Therapeutics media release, company plans to submit Investigational New Drug (IND) applications for LTX-002 and LTX-001 by the end of 2024 and commence first-in-human clinical trials in early 2025.
30 Oct 2024 According to a Leal Therapeutics media release, company announced a $45 million financing. The Financing supports advancement of lead programs LTX-002 and LTX-001 to first-in-human trials.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com